Publication
FOXD1 upregulates DARS2-mediated glycolysis to drive cisplatin resistance in bladder cancer.
Xianyong Li, Mingqiang Su, Jingxian Luo, Dengjun Han, Liangliang Qing, Dayong Zhang, Sheng Liu, Junfa Liu, Guangqing Fu
Urologic oncologySep 5, 2026PMID 42701051doi:10.1016/j.urolonc.2026.07.027 Journal ArticlepubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 16, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260916-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
BACKGROUND: Chemotherapy remains the most effective systemic treatment for bladder cancer (BLCA), with cisplatin as the primary agent. However, the frequent development of cisplatin resistance limits its clinical efficacy. Forkhead box D1 (FOXD1) is implicated in BLCA progression, yet its role in…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Bladder Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available
No curated evidence item cites this publication.